Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:JNJ
- CUSIP: 47816010
- Web: www.jnj.com
- Market Cap: $343.54 billion
- Outstanding Shares: 2,693,833,000
- 50 Day Moving Avg: $124.43
- 200 Day Moving Avg: $119.53
- 52 Week Range: $109.32 - $129.00
Sales & Book Value:
- Trailing P/E Ratio: 21.29
- Foreward P/E Ratio: 16.63
- P/E Growth: 2.78
- Annual Revenue: $72.17 billion
- Price / Sales: 4.76
- Book Value: $26.10 per share
- Price / Book: 4.89
- Annual Dividend: $3.20
- Dividend Yield: 2.6%
- EBIDTA: $25.12 billion
- Net Margins: 22.78%
- Return on Equity: 25.61%
- Return on Assets: 13.40%
- Debt-to-Equity Ratio: 0.32%
- Current Ratio: 2.73%
- Quick Ratio: 2.36%
- Average Volume: 6.10 million shs.
- Beta: 0.74
- Short Ratio: 2.31
Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson announced a quarterly dividend on Thursday, April 27th. Stockholders of record on Tuesday, May 30th will be paid a dividend of $0.84 per share on Tuesday, June 13th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.63%. The ex-dividend date is Thursday, May 25th. This is a boost from Johnson & Johnson's previous quarterly dividend of $0.80. View Johnson & Johnson's Dividend History.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) released its quarterly earnings results on Tuesday, April, 18th. The company reported $1.83 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.06. The company had revenue of $17.77 billion for the quarter, compared to analyst estimates of $18.02 billion. Johnson & Johnson had a net margin of 22.78% and a return on equity of 25.61%. Johnson & Johnson's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.68 EPS. View Johnson & Johnson's Earnings History.
When will Johnson & Johnson make its next earnings announcement?
Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?
17 brokerages have issued 1-year price targets for Johnson & Johnson's stock. Their predictions range from $112.80 to $145.00. On average, they anticipate Johnson & Johnson's share price to reach $130.68 in the next twelve months. View Analyst Ratings for Johnson & Johnson.
What are analysts saying about Johnson & Johnson stock?
Here are some recent quotes from research analysts about Johnson & Johnson stock:
- 1. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
- 2. According to Zacks Investment Research, "J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues. While Pfizer’s launch of biosimilar Remicade creates some uncertainty regarding the segment’s sales growth in 2017, we believe that the impact may be manageable. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates have remained mostly stable lately ahead of the Q4 earnings results. J&J has a positive record of earnings surprises in recent quarters. J&J's shares have surpassed that of large-cap pharma industry in 2016. However, headwinds persist in the form of generics and biosimilar competition and pricing pressure." (1/9/2017)
- 3. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)
Are investors shorting Johnson & Johnson?
Johnson & Johnson saw a decline in short interest during the month of April. As of April 28th, there was short interest totalling 14,370,293 shares, a decline of 17.4% from the April 13th total of 17,397,650 shares. Based on an average trading volume of 6,259,588 shares, the short-interest ratio is presently 2.3 days. Currently, 0.5% of the shares of the stock are sold short.
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include Novartis AG (NVS), Pfizer (PFE), Merck & Co. (MRK), Sanofi SA (SNY), AbbVie (ABBV), GlaxoSmithKline plc (GSK), Bristol-Myers Squibb Co (BMY), AstraZeneca plc (AZN), Eli Lilly and Co (LLY), Shire PLC (SHPG), GW Pharmaceuticals PLC- (GWPH), Aerie Pharmaceuticals (AERI), Impax Laboratories (IPXL), TherapeuticsMD (TXMD), Retrophin (RTRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI) and Zogenix (ZGNX).
Who owns Johnson & Johnson stock?
Johnson & Johnson's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.28%), BlackRock Inc. (6.26%), State Street Corp (5.95%), State Farm Mutual Automobile Insurance Co. (1.40%), Bank of New York Mellon Corp (1.38%) and Wellington Management Group LLP (1.23%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.
Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?
Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Nordea Investment Management AB, Pioneer Investment Management Inc., Boston Partners, Parametric Portfolio Associates LLC, Wellington Management Group LLP, Morgan Stanley and Bank of New York Mellon Corp. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso, Gary J Pruden, Paulus Stoffels and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.
Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?
Johnson & Johnson's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Swiss National Bank, Alliancebernstein L.P. and Karp Capital Management Corp. View Insider Buying and Selling for Johnson & Johnson.
How do I buy Johnson & Johnson stock?
Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Johnson & Johnson stock cost?
One share of Johnson & Johnson stock can currently be purchased for approximately $127.53.
Earnings History for Johnson & Johnson (NYSE:JNJ)Earnings History by Quarter for Johnson & Johnson (NYSE:JNJ)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|7/18/2017|| || || || || || || || |
|4/18/2017||Q1 17||$1.77||$1.83||$18.02 billion||$17.77 billion||View||N/A|
|1/24/2017||Q416||$1.56||$1.58||$18.28 billion||$18.10 billion||View||N/A|
|10/18/2016||Q316||$1.65||$1.68||$17.71 billion||$17.80 billion||View||Listen|
|7/19/2016||Q216||$1.68||$1.74||$17.98 billion||$18.50 billion||View||Listen|
|4/19/2016||Q116||$1.65||$1.68||$17.50 billion||$17.50 billion||View||Listen|
|1/26/2016||Q415||$1.42||$1.44||$17.88 billion||$17.80 billion||View||Listen|
|10/13/2015||Q315||$1.45||$1.49||$17.47 billion||$17.10 billion||View||Listen|
|7/14/2015||Q215||$1.69||$1.71||$17.76 billion||$17.80 billion||View||Listen|
|4/14/2015||Q115||$1.54||$1.56||$17.31 billion||$17.37 billion||View||Listen|
|1/20/2015||Q414||$1.25||$1.27||$18.59 billion||$18.30 billion||View||Listen|
|10/14/2014||Q314||$1.42||$1.50||$18.41 billion||$18.50 billion||View||Listen|
|7/15/2014||Q214||$1.54||$1.66||$18.86 billion||$19.50 billion||View||N/A|
|4/15/2014||Q114||$1.48||$1.54||$18.00 billion||$18.10 billion||View||N/A|
|1/21/2014||Q413||$1.20||$1.24||$17.95 billion||$18.40 billion||View||N/A|
|10/15/2013||Q313||$1.32||$1.36||$17.46 billion||$17.60 billion||View||N/A|
|7/16/2013||Q2 2013||$1.39||$1.48||$17.71 billion||$17.90 billion||View||N/A|
|4/16/2013||Q1 2013||$1.41||$1.44||$17.46 billion||$17.50 billion||View||N/A|
|1/22/2013||Q4 2012||$1.17||$1.19||$17.67 billion||$17.60 billion||View||N/A|
Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
2017 EPS Consensus Estimate: $6.99
2018 EPS Consensus Estimate: $7.79
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
|Dividend Growth:||6.70% (3 Year Average)|
|Payout Ratio:||54.42% (Trailing 12 Months of Earnings) |
45.01% (Based on This Year's Estimates)
41.72% (Based on Next Year's Estimates)
|Track Record:||54 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Johnson & Johnson (NYSE:JNJ)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.11%Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership Percentage: 65.30%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/15/2017||Paulus Stoffels||VP||Sell||22,000||$117.29||$2,580,380.00|| |
|10/21/2016||Charles Prince||Director||Buy||875||$114.11||$99,846.25|| |
|7/26/2016||Dominic J Caruso||VP||Sell||41,146||$125.01||$5,143,661.46|| |
|7/22/2016||Ronald A Kapusta||CAO||Sell||2,935||$125.01||$366,904.35|| |
|6/7/2016||Gary J Pruden||VP||Sell||9,735||$116.03||$1,129,552.05|| |
|6/7/2016||Ronald A Kapusta||CAO||Sell||3,000||$115.79||$347,370.00|| |
|5/10/2016||Ronald A Kapusta||CAO||Sell||3,957||$114.77||$454,144.89|| |
|2/17/2016||Paulus Stoffels||insider||Sell||125,000||$102.43||$12,803,750.00|| |
|2/3/2016||Peter Fasolo||VP||Sell||151,385||$104.12||$15,762,206.20|| |
|10/23/2015||Ronald A. Kapusta||CAO||Sell||6,239||$99.68||$621,903.52|| |
|6/2/2015||Charles Prince||Director||Buy||2,500||$99.22||$248,050.00|| |
|4/28/2015||Paulus Stoffels||Insider||Sell||187,250||$100.73||$18,861,692.50|| |
|9/10/2014||James Cullen||Director||Sell||2,446||$104.12||$254,677.52|| |
|5/5/2014||Stephen Cosgrove||Insider||Sell||22,000||$100.05||$2,201,100.00|| |
|3/14/2014||Peter Fasolo||VP||Sell||6,824||$93.15||$635,655.60|| |
|8/14/2013||Stephen Cosgrove||Insider||Sell||17,200||$91.39||$1,571,908.00|| |
|8/5/2013||Michael Ullmann||VP||Sell||16,140||$93.68||$1,511,995.20|| |
|7/25/2013||Paulus Stoffels||Insider||Sell||45,440||$92.40||$4,198,656.00|| |
|7/18/2013||Dominic J Caruso||CFO||Sell||30,000||$90.31||$2,709,300.00|| |
|11/12/2012||James Cullen||Director||Sell||13,900||$69.70||$968,830.00|| |
Headline Trends for Johnson & Johnson (NYSE:JNJ)
Latest Headlines for Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (JNJ) Chart for Thursday, May, 25, 2017